Publications
169
Citations
7,830
Est. group size
~3
Recurring co-author estimate
Active years
30
Publishing since 1997
Typically publishes in teams of ~17 · 7% small-team papers (≤3 authors) · across 35 venues
- The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis
Circulation · 2026
- Aficamten Reduces Eligibility for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy: Long-Term Outcomes from FOREST-HCM
medRxiv · 2026
- Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
JACC Heart Failure · 2025
- Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta‐Analysis
Journal of the American Heart Association · 2025
- Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for Up to 128 Weeks
JACC. Cardiovascular imaging · 2025
- Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
JACC Heart Failure · 2025
- Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy
Circulation Genomic and Precision Medicine · 2025
- Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials
Heart Rhythm · 2025
- Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation
European Heart Journal · 2025
- Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial
Circulation Genomic and Precision Medicine · 2025
- Long-Term Response of Obstructive Hypertrophic Cardiomyopathy Patients to Mavacamten Based on Sex
JACC Heart Failure · 2025
- Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM
Circulation Heart Failure · 2025
- LONG-TERM FAVORABLE CARDIAC REMODELING IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS TREATED WITH MAVACAMTEN FOR UP TO 128 WEEKS: INSIGHTS FROM VALOR-HCM TRIAL
Journal of the American College of Cardiology · 2025
- Response to Mavacamten in Patients With High Baseline Left Ventricular Filling Pressures in the EXPLORER-HCM Trial
Circulation Cardiovascular Imaging · 2025
- Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy
Circulation · 2025
- Circulation×42
- Journal of the American College of Cardiology×27
- Journal of Cardiac Failure×8
- JACC Heart Failure×6
- JAMA Cardiology×4
- Anjali Owens
Medicine · University of Michigan
- Caroline Coats
Medicine · University of Michigan
- Martin S. Maron
Medicine · University of Michigan
- Albree Tower‐Rader
Medicine · University of Michigan
- Adam Helms
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile